In patients with both homozygous and heterozygous familial hypercholesterolaemia (FH), statins with or without ezetimibe are now the mainstay pharmacological therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, combined with lipoprotein apheresis in homozygotes and statin-refractory heterozygotes. These therapies have helped to improve outcomes, but new treatment options are
urgently needed, as FH patients continue to be at high risk of premature death due to cardiovascular disease (CVD).
HEART UK – The Cholesterol Charity – has provided editorial support and review of this sponsored FH series.
This article was made possible by an unrestricted educational grant by Sanofi, who had no control over content.
